Velsen-Noord, Netherlands
Longeveron is a clinical stage biotechnology company based in the Netherlands, developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions. Their investigational therapeutic candidate, Lomecel-B® (laromestrocel), is a proprietary, scalable, allogeneic cellular therapy being evaluated for Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer’s Disease, and Age-Related Frailty. The company was founded to address the needs of vulnerable populations, including children and the elderly. Longeveron was named a finalist in the XPRIZE Healthspan Global Competition and will receive a $1,000,000 milestone award. The company is committed to advancing stem cell therapies that bring hope to those in need. Longeveron was founded in 2026.
Browsing, company names, locations and sectors are always free. A free account adds 5 contact releases every month — e-mail and phone, view or export. Need more? Contact packs start at 19 € for 50, or upgrade to a monthly plan.
Yes — no card required. Browsing is always free, and a free account adds 5 contact releases every month.
Your first 5 contact releases each month are included in the free account. After that, packs start at 19 € for 50 contacts (view or export), or a monthly plan for regular use.
Companies are harvested from the open web — registers, websites and industry directories — not self-registered sign-ups. Contact details are shown only once you use a release or credit, never invented.